WO2016009095A1 - Tissus textiles fonctionnels - Google Patents
Tissus textiles fonctionnels Download PDFInfo
- Publication number
- WO2016009095A1 WO2016009095A1 PCT/ES2015/070328 ES2015070328W WO2016009095A1 WO 2016009095 A1 WO2016009095 A1 WO 2016009095A1 ES 2015070328 W ES2015070328 W ES 2015070328W WO 2016009095 A1 WO2016009095 A1 WO 2016009095A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- endorphin
- textile
- textile fabric
- bioactive molecule
- fabric
- Prior art date
Links
- 239000004753 textile Substances 0.000 title claims abstract description 90
- 239000004744 fabric Substances 0.000 title claims abstract description 60
- 101800005049 Beta-endorphin Proteins 0.000 claims abstract description 42
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims abstract 15
- 230000000975 bioactive effect Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 14
- 229920000742 Cotton Polymers 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229920002994 synthetic fiber Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920000297 Rayon Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 239000012209 synthetic fiber Substances 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920002334 Spandex Polymers 0.000 claims description 3
- 235000009120 camo Nutrition 0.000 claims description 3
- 235000005607 chanvre indien Nutrition 0.000 claims description 3
- 239000011487 hemp Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000002964 rayon Substances 0.000 claims description 3
- 210000002268 wool Anatomy 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 abstract description 20
- 230000036642 wellbeing Effects 0.000 abstract description 9
- 102400000748 Beta-endorphin Human genes 0.000 description 27
- 239000000463 material Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000002304 perfume Substances 0.000 description 8
- 108010049140 Endorphins Proteins 0.000 description 7
- 102000009025 Endorphins Human genes 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920001872 Spider silk Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- -1 yarn Substances 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- GEHMBYLTCISYNY-UHFFFAOYSA-N Ammonium sulfamate Chemical compound [NH4+].NS([O-])(=O)=O GEHMBYLTCISYNY-UHFFFAOYSA-N 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000003763 resistance to breakage Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
- D06M15/15—Proteins or derivatives thereof
Definitions
- the present invention falls within the field of materials, in particular the field of textile fibers or materials, in particular the invention relates to those textile materials or textile fibers used for the manufacture of functional textile elements comprising at least one molecule.
- the present invention relates to a fabric made from textile fibers comprising at least one biologically active molecule, as well as to the textile garment made from said fabric.
- the present invention also relates to a process for the manufacture of textile fabrics object of the invention comprising the bioactive molecule.
- it refers to the application of at least one peptide, such as an opioid neurotransmitter of the endorphin type, in a cotton-based fabric, using a pipette with an optimized solution and concentration.
- the present invention also relates to the use of said textile fabrics to manufacture textile garments that produce in the individual that they carry a feeling of general well-being.
- the present invention thus provides a practical and simple solution that reports well-being in the users or patients who wear the garments as it had not been seen in the state of the art to date.
- the effects it produces in the users of these tissues, the application of these molecules consist in the deceleration of the growth of cancer cells, promote the feeling of well-being, increase relaxation and inhibit the pain, and on the other hand produce feelings of placidity, joy, pleasure, desire to live and good humor, about people who are in contact with the tissue in question.
- the procedures of ennoblement can be divided into purely mechanical and wet.
- the liquids used are mainly water and, to a lesser extent, solvents, as well as liquefied ammonia gas.
- Another important element is water vapor.
- a large number of chemical products, dyes and chemical auxiliary agents are used.
- ES2245795 discloses a composition
- a composition comprising a peptide or a deposition adjuvant protein with a high affinity with the fibers or a surface, and a functional agent bound / adsorbed to the peptide or the adjuvant protein of the deposition, wherein said deposition peptide or protein is cellulose or the binding domain thereof, and said functional agent is selected from a perfume, an encapsulated perfume, a photoprotective agent, a soil-releasing polymer, a dirt repellent agent, a compound Fabric softener, an insecticide, a fungicide, antioxidants or pigment fixatives.
- a functional agent in the context of this invention is a compound that provides a desirable effect for a fiber, fabric or surface not for the individual wearing it.
- patent ES2087996 discloses a method for applying an insecticide to a fibrous textile material, characterized by encapsulating the insecticide within microcapsules of a substance that is a food, to which insects or their larvae are attracted. , and joining the microcapsules to the fibers of the material by means of a binding agent that does not prevent the release of the insecticide when the microcapsules are devoured.
- composition comprises a polymer consisting of polyethyleneimine, a neutralizer of the bad smell consisting of an aliphatic aldehyde and an aqueous carrier, wherein said composition is practically free of any material that could dirty or stain fabrics.
- US2008175991 discloses a method of manufacturing a coated cellulose textile, whereby a silk peptide is polymerized as in a building block to develop a silk peptide / building nanoparticle block, said nanoparticles are then used to cover the textile.
- the resulting textile exhibits a high level of wrinkle recovery angle and / or resistance to breakage, all without the use of N-methylol compounds, including ureas and formaldehydes. In this case the advantage is over the fabric again.
- WO2012131745 discloses a binder (which comprises sulfamic acid, ammonium sulfamate and ammonium sulfate) and the production process of fabrics containing cyclodextrins fixed with the binder. More precisely, the present invention makes it possible to fix a binder to natural, synthetic or artificial fibers, and by means of thermal processes fix cyclodextrins with the same binder, giving rise to suitable tissues to incorporate active ingredients and to free them in time. Peculiar characteristics of said binder are its abilities to interact with various types of tissues, regardless of their composition, and with several types of cyclodextrin.
- This patent application discloses a method for treating spider silk filament, for use as a thread or composition in the manufacture of cosmetics, medical elements, textiles, and industrial applications, where the spider silk filament, from genetically modified organisms, it is treated with at least one component selected from the group consisting of vitamins, hormones, antioxidants, chelating agents, antibiotics, preservatives, fragrances, dyes, pigments, magnetic nanoparticles, nanocrystals, adhesion enhancers cellular, thermal insulators, shrinkage agents and cosmetic, medical or dermatological active substances. Fabrics obtained by this method are stronger, biocompatible, biodegradable and have superior thermal conductivity.
- the treated spider silk filament can also be applied in an oil-petticoat or water-in-oil protective cream that is hypoallergenic and ensures firmer skin, but has no effect directly on the skin from the woven garment.
- JPH09158041 discloses a method of obtaining clothing, such as underwear sufficiently capable of masking body odor due to perspiration, etc., without imparting an unpleasant sensation to a user by impregnating the clothing with a perfume precursor capable of producing a perfume component by hydrolysis.
- the solution proposed by this patent is that the functional clothing is obtained by impregnating a fibrous material or a knitted fabric that constitutes the clothing with a perfume precursor such as a glycoside of a perfume, a glyceride or a peptide derivative.
- the perfume precursor is preferably impregnated in an amount of 0.01-20% by weight.
- the clothing or the fibrous material can be impregnated even with an enzyme capable of breaking down the perfume precursor to regulate the amount of an aroma released.
- KR20040063730 Another patent of the next state of the art is KR20040063730.
- This patent application discloses a functional textile that contains functional medical materials that are characterized by stimulating the immune system and the lymphatic system to control functions of vital importance, which has anti-cancer property, for disease prevention, which has the function of disease recovery, vital rhythm control, prevent aging and increased autoimmunity.
- the functional medical materials are ribonucleic acid, oligosaccharides, chitosan, polysaccharide, amino acid, oligopeptides, peptideglycans, probiotics of useful microorganisms, functional plants and an algae extract.
- patent KR20040064170 The last patent detected by the researchers of the present invention is patent KR20040064170.
- This patent application is related to the previous one and discloses a functional cotton that contains functional medical materials and is characterized by stimulating the immune system and the lymphatic system to control the function of vital importance, which has anti-cancer property, disease prevention , which has the function of disease recovery, vital rhythm control, preventing aging and increasing autoimmunity.
- Functional medical materials are ribonucleic acid, oligosaccharides, chitosan, polysaccharide, amino acid, oligopeptides, peptidoglycans, probiotics of useful microorganisms, functional plants and an algae extract.
- Figure 1. Shows a mass spectrum in which a defined peak is reflected in a range between 3464-3465 Daltons characteristic of ⁇ -endorphin that allows it to be used as a control measure to track the presence of the compound in the tissue in the following days.
- Figure 2. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 6h of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c).
- the tissue sample was treated as follows: Extraction by incubation with ACN: H 2 0 (1: 1) for 30 minutes at a controlled temperature of 22.52C. After incubation, it has been dried in a centrifugal desiccator, and the sample has been resuspended in 30 ⁇ . TFA 0.1% in water. The sample has been analyzed by splashing after desalting by R2R3 column (reverse phase, similar to C18 / C8).
- Figure 4. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 48h of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c). The tissue sample was treated in the same manner as Figure 2.
- Figure 5. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 72h of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c). The tissue sample was treated in the same manner as Figure 2.
- Figure 6. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 10 days of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c). The tissue sample was treated in the same manner as Figure 2.
- textile fibers are understood regardless of the set of filaments or strands that can be used to form threads and with them fabrics, either by spinning or by other physical or chemical processes.
- textile fibers are the basic structures of textile fabrics.
- Textile fiber is considered any material whose length is much greater than its diameter and which can be spun.
- textile fabric is considered to be the fabric made from textile fibers, that is, the textile product as a result of weaving textile threads, filaments or fibers.
- textile garment is considered to be any final material obtained from the textile fabric object of the present invention that will be placed in contact with the user's skin.
- bioactive molecule is considered to be any compound, molecular entity, ingredient or active agent whatever its origin - human, animal, vegetable, chemical or other - to which an appropriate activity beneficial to health is attributed and / or promote the feeling of well-being, increase relaxation and inhibit pain or produce feelings of placidity.
- the invention relates to those textile materials or textile fibers used for the manufacture of functional textile fabrics comprising at least one biologically active molecule.
- the biologically active molecule incorporated in the textile tissue is preferably a peptide, such as an opioid neurotransmitter of the endorphin type. More preferably ⁇ -endorphin.
- Beta endorphin is an endogenous opioid hormone and neurotransmitter that is produced in the central nervous system. It acts primarily as a moderator of pain, reducing the transmission and effectiveness of sensory stimuli. Its receptors are located along the central and peripheral nervous system and are called opioid receptors, specifically ⁇ receptors. When the neurotransmitter is attached to the receptor it causes Supra peripheral spinal analgesia that results, among other effects, in a dilation of blood vessels, euphoria and sedation. It has great influence on the immune system. Leukocytes are extremely sensitive to endorphins, for which they have specific receptors. Endorphins increase the production and efficacy of T cells, which keep viruses, bacteria and cancer cells at bay and also stimulate the synthesis of endogenous antioxidants.
- the present invention relates to a fabric made from textile fibers comprising at least one biologically active molecule, as well as to the textile garment made from said fabric.
- the present invention also relates to a process for the manufacture of textile fabrics object of the invention comprising the bioactive molecule.
- it refers to the application of at least one peptide, such as an opioid neurotransmitter of the endorphin type, in a cotton-based fabric, using a pipette with an optimized solution and concentration.
- the present invention also relates to the use of said textile fabrics to manufacture textile garments that produce in the individual that they carry a feeling of general well-being.
- the present invention therefore provides a practical and simple solution that reports well-being in the users or patients wearing the garments made from the tissue impregnated with a concentration of Beta endorphins.
- the effects it produces on the users of these tissues, the application of these molecules consist of the slowdown of the growth of cancer cells, promote the feeling of well-being, increase relaxation and inhibit pain, and on the other hand produce feelings of placidity, joy , pleasure, desire to live and good humor, about people who are in contact with the tissue in question.
- the concentration of ⁇ -endorphin is 0.1 to 500 ⁇ g / ⁇ L in H 2 0 and preferably 2 ⁇ g / ⁇ L of ⁇ -endorphin in H 2 0. This concentration is easily detected by a MALDI spectrometer. TOF Bruker Autoflex III Smartbeam, so that it can be verified that the textile fabric effectively comprises endorphin.
- a textile fabric comprising a composition of at least one bioactive molecule that is ⁇ -endorphin in which the composition of the bioactive molecule is from 0.1 to 500 ⁇ g / ⁇ L of ⁇ -endorphin in H 2 0 and preferably 2 ⁇ g / ⁇ L of ⁇ -endorphin in H 2 0.
- the textile fabric is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp or biso, or artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, Taffeta or gauze.
- the textile fabric is cotton.
- the textile fabric of step a.-) is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp or biso, or artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, taffeta or gauze.
- the textile fabric is cotton.
- the application of step b.-) is carried out with a device selected from the group consisting of pipette, swab, dropper, etc.
- it is done with an automatic pipette, with solid phase extraction by means of reverse-phase Zip-Tip ® tips.
- the application occurs directly in the fabric, so that it is absorbed by the tissue, the molecule being attached to the fibers of the textile fabric itself.
- the process object of the present invention is characterized in that the addition of ⁇ -endorphin from step b.-) is carried out with an automatic pipette.
- the process object of the present invention is characterized in that the addition of ⁇ -endorphin of step b.-) is carried out by atomizing a solution with the bioactive molecule on the tissue, waiting a few minutes to its absorption
- ⁇ -endorphin from step b.- is performed at a concentration of 2ug ⁇ ⁇ -endorphin L H 2 0.
- Another aspect of the present invention is a textile garment suitable for absorbing and releasing a bioactive molecule of the ⁇ -endorphin type that is obtained by the process of the present invention.
- the aforementioned textile garment is suitable for absorbing and releasing a bioactive molecule of the ⁇ -endorphin type and is selected from the group consisting of dressings, gauze, sheets and clothing.
- Another aspect of the present invention is the use of the textile fabric object of the present invention to manufacture a textile garment suitable for absorbing and releasing a bioactive molecule of the ⁇ -endorphin type.
- EXAMPLE 1 Test of adhesion or fixation of ⁇ -endorphin to textile fabric.
- the amount charged was 7 ⁇ , with elution in 0.5 ⁇ matrix (synapine acid, 10 mg / ml, in ACN: 0.1% TFA [70:30]).
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Abstract
la présente invention concerne un tissu textile confectionné à partir de fibres textiles, qui comprend au moins une molécule biologiquement active. La présente invention concerne également un procédé de fabrication des tissus textiles objets de l'invention, lesquels comprennent au moins un peptide tel qu'un neurotransmetteur opiacé du type β-endorphine. La présente invention concerne en outre l'utilisation desdits tissus tissés pour fabriquer des vêtements en textiles qui produisent chez l'individu qui les porte une sensation de bien-être général.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201431073 | 2014-07-16 | ||
ES201431073A ES2518765B2 (es) | 2014-07-16 | 2014-07-16 | Tejidos textiles funcionales |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016009095A1 true WO2016009095A1 (fr) | 2016-01-21 |
Family
ID=51831085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2015/070328 WO2016009095A1 (fr) | 2014-07-16 | 2015-04-21 | Tissus textiles fonctionnels |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2518765B2 (fr) |
WO (1) | WO2016009095A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641956A (zh) * | 2017-09-08 | 2018-01-30 | 安徽龙盛纺织科技有限公司 | 一种雪纺面料压绉印花方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019087124A1 (fr) * | 2017-11-01 | 2019-05-09 | Clexio Biosciences Ltd. | Structures fibreuses finies et leur procédés d'utilisation et de préparation |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2005260A (en) | 1932-12-30 | 1935-06-18 | Atlas Powder Co | Press mechanism |
ES2087996T3 (es) | 1990-01-18 | 1996-08-01 | Cpc International Inc | Tratamiento de materiales textiles. |
WO2003103550A2 (fr) * | 2002-06-08 | 2003-12-18 | Ian Robert Thomson | Systeme d'administration de medicament ou de composition augmentant le bien-etre |
KR20040063730A (ko) | 2003-01-08 | 2004-07-14 | 손영석 | 기능성 원단 |
KR20040064170A (ko) | 2003-01-09 | 2004-07-16 | 손영석 | 기능성 솜 |
EP1498113A1 (fr) * | 2003-07-17 | 2005-01-19 | L'oreal | Utilisation de béta-endorphine et/ou d'agents exercant une activité béta-endorphine-like en cosmétique et dermatologie |
DE10329685A1 (de) * | 2003-07-02 | 2005-01-20 | Cognis Deutschland Gmbh & Co. Kg | Mikrokapseln (XXV) |
ES2245795T3 (es) | 1996-07-01 | 2006-01-16 | Unilever N.V. | Composicion detergente. |
US20080175991A1 (en) | 2007-01-22 | 2008-07-24 | The Hong Kong Polytechnic University | Cellulosic fabric with silk peptide/building block nanopolymer |
MX2012003293A (es) | 2009-09-18 | 2012-04-30 | Procter & Gamble | Composiciones refrescantes que comprenden polimeros que absorben el mal olor y neutralizadores del mal olor. |
US20120238942A1 (en) * | 2009-12-04 | 2012-09-20 | Michael Horstmann | Transdermal therapeutic System for the Administration of Peptides |
WO2012131745A1 (fr) | 2011-03-31 | 2012-10-04 | GIANIS S.r.L. | Liant et processus de production de tissus contenant des cyclodextrines fixées par ledit liant |
WO2013147590A2 (fr) | 2012-03-27 | 2013-10-03 | Essaidi Jalila | Procédé pour le traitement de filament de soie d'araignée pour utiliser comme fil ou composition dans la fabrication de produits cosmétiques, médicaux, textiles ou dans des applications industrielles comme des tissus de cellules bio-artificielles ou de la peau artificielle à base de soie d'araignée (recombinée) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2780073B1 (fr) * | 1998-06-19 | 2000-09-01 | Dim Sa | Textile bio-actif comportant dans ses fibres de la proteine de soie et des microcapsules de produit actif |
EP2444549A1 (fr) * | 2010-10-20 | 2012-04-25 | Stazione Sperimentale per la Seta | Matériaux textiles dotés d'une protection bioactive |
-
2014
- 2014-07-16 ES ES201431073A patent/ES2518765B2/es not_active Expired - Fee Related
-
2015
- 2015-04-21 WO PCT/ES2015/070328 patent/WO2016009095A1/fr active Application Filing
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2005260A (en) | 1932-12-30 | 1935-06-18 | Atlas Powder Co | Press mechanism |
ES2087996T3 (es) | 1990-01-18 | 1996-08-01 | Cpc International Inc | Tratamiento de materiales textiles. |
ES2245795T3 (es) | 1996-07-01 | 2006-01-16 | Unilever N.V. | Composicion detergente. |
WO2003103550A2 (fr) * | 2002-06-08 | 2003-12-18 | Ian Robert Thomson | Systeme d'administration de medicament ou de composition augmentant le bien-etre |
KR20040063730A (ko) | 2003-01-08 | 2004-07-14 | 손영석 | 기능성 원단 |
KR20040064170A (ko) | 2003-01-09 | 2004-07-16 | 손영석 | 기능성 솜 |
DE10329685A1 (de) * | 2003-07-02 | 2005-01-20 | Cognis Deutschland Gmbh & Co. Kg | Mikrokapseln (XXV) |
EP1498113A1 (fr) * | 2003-07-17 | 2005-01-19 | L'oreal | Utilisation de béta-endorphine et/ou d'agents exercant une activité béta-endorphine-like en cosmétique et dermatologie |
US20080175991A1 (en) | 2007-01-22 | 2008-07-24 | The Hong Kong Polytechnic University | Cellulosic fabric with silk peptide/building block nanopolymer |
MX2012003293A (es) | 2009-09-18 | 2012-04-30 | Procter & Gamble | Composiciones refrescantes que comprenden polimeros que absorben el mal olor y neutralizadores del mal olor. |
US20120238942A1 (en) * | 2009-12-04 | 2012-09-20 | Michael Horstmann | Transdermal therapeutic System for the Administration of Peptides |
WO2012131745A1 (fr) | 2011-03-31 | 2012-10-04 | GIANIS S.r.L. | Liant et processus de production de tissus contenant des cyclodextrines fixées par ledit liant |
WO2013147590A2 (fr) | 2012-03-27 | 2013-10-03 | Essaidi Jalila | Procédé pour le traitement de filament de soie d'araignée pour utiliser comme fil ou composition dans la fabrication de produits cosmétiques, médicaux, textiles ou dans des applications industrielles comme des tissus de cellules bio-artificielles ou de la peau artificielle à base de soie d'araignée (recombinée) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641956A (zh) * | 2017-09-08 | 2018-01-30 | 安徽龙盛纺织科技有限公司 | 一种雪纺面料压绉印花方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2518765B2 (es) | 2015-03-05 |
ES2518765A1 (es) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singh et al. | Cosmetotextiles: state of art | |
ES2694430T3 (es) | Utilización de un artículo a base de una composición polimérica | |
CN104294595A (zh) | 一种抗菌防臭纺织品的生产工艺 | |
CN105113075A (zh) | 一种纺织材料 | |
Buschmann et al. | Medical, cosmetic and odour resistant finishes for textiles | |
JP3022880B1 (ja) | 角質層の新陳代謝を促進する被服並びにマイクロカプセルの付着方法 | |
CN105177855A (zh) | 一种铜氨纤维面膜专用非织造布 | |
KR20080028214A (ko) | 기능성 감물 가공 원단 및 그 제조방법 | |
WO2016009095A1 (fr) | Tissus textiles fonctionnels | |
Han et al. | Grafting cosmetic active ingredients for the functionalization of cosmetotextiles | |
TWI279226B (en) | Dressings which can be applied several times to textile fibres and textile fabrics | |
CN105708254B (zh) | 功效性磁疗睡袋 | |
Chandrasekaran et al. | Analysis of eco-friendly medicinal herb extracts and essential oil applications on textile products for healthcare applications | |
Jamal et al. | Cosmetotextiles: A wearable skin care | |
CN107476066A (zh) | 一种持久清香的抗菌面料 | |
CN103767080A (zh) | 一种具有护肤保健消除中老年体味功能的暖棉内衣及其制备方法 | |
CN109023930A (zh) | 一种保健功能性材料及其制备方法和应用 | |
JP2003048264A (ja) | 繊維構造体 | |
CN204736497U (zh) | 一种具有隔离不良气味的功能布料结构 | |
JP2006152464A (ja) | 繊維構造物 | |
JP2002339252A (ja) | 寝具用繊維製品 | |
CN206266760U (zh) | 一种自芳香天然抗菌除臭纤维 | |
KR102459187B1 (ko) | 아스코르브산이 함침된 직물지의 제조방법 및 그 제법에 의해 아스코르브산이 함유된 직물지 | |
Dorugade et al. | Cosmetotextiles: A New Functionality of Garments for Well-Being | |
KR100442013B1 (ko) | 옥정수에 의한 섬유가공방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15729206 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/06/2017) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15729206 Country of ref document: EP Kind code of ref document: A1 |